<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00881946</url>
  </required_header>
  <id_info>
    <org_study_id>PKB112835</org_study_id>
    <nct_id>NCT00881946</nct_id>
  </id_info>
  <brief_title>Repeat Dose Safety Study for Compound to Treat Hematologic Cancer</brief_title>
  <official_title>A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral AKT Inhibitor GSK2110183 in Subjects With Any Hematologic Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Accenture</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Accenture</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety and tolerability of repeat doses of&#xD;
      compound GSK2110183 in subjects with hematologic cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physical exam</measure>
    <time_frame>Screening, Days -3, 8, At the start of each additional Cycle</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram (ECG)</measure>
    <time_frame>Days -3, -2, -1, 8, 15, At the start of each additional Cycle</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Screening, Days -3, -2, -1, 8, 15, At the start of each additional Cycle</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Transthoracic Echocardiogram (TTE)/Multiple Gated Acquisition (MUGA) Scans</measure>
    <time_frame>Screening, Additionally as needed</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory assessments</measure>
    <time_frame>Screening, Days -3, 1, 8, 15, At the start of each additional Cycle</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ECOG Peformance Status</measure>
    <time_frame>Screening, Days -3, 8, At the start of each additional Cycle</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK - Maximum observed plasma concentraion (Cmax)</measure>
    <time_frame>Days -3, -2, -1, 8, 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK - time to Cmax [tmax] (Maximum observed plasma concentration)</measure>
    <time_frame>Days -3, -2, -1, 8, 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK - Area under the plasma concentration-time curve (AUC(0-t))</measure>
    <time_frame>Days -3, -2, -1, 8, 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK - Apparent terminal phase elimination rate constant</measure>
    <time_frame>Days -3, -2, -1, 8, 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK - Apparent terminal phase half-life (t1/2)</measure>
    <time_frame>Days -3, -2, -1, 8, 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK - oral clearance (CL/F)</measure>
    <time_frame>Days -3, -2, -1, 8, 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolite Profiling</measure>
    <time_frame>Days -3, 8</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>GSK2119183</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK21110183</intervention_name>
    <description>Starting Dose = 25mg once daily with dose escalation until unacceptable toxicity develops</description>
    <arm_group_label>GSK2119183</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent is provided.&#xD;
&#xD;
          2. Male or female who is at least 18 years of age or older.&#xD;
&#xD;
          3. Histologically- or cytologically-confirmed diagnosis of a hematologic malignancy -&#xD;
             that has relapsed or is refractory after standard therapy, AND that is not associated&#xD;
             with human immunodeficiency virus (HIV) infection or solid organ transplant,&#xD;
             including:&#xD;
&#xD;
               -  chronic lymphocytic leukemia (CLL),&#xD;
&#xD;
               -  chronic myelogenous leukemia (CML),&#xD;
&#xD;
               -  multiple myeloma (MM),&#xD;
&#xD;
               -  non-Hodgkin's lymphoma (NHL),&#xD;
&#xD;
               -  Hodgkin's lymphoma, or&#xD;
&#xD;
               -  Other hematologic malignancy excluding:&#xD;
&#xD;
               -  acute leukemia of any type&#xD;
&#xD;
               -  CML blast crisis&#xD;
&#xD;
               -  myelodysplastic syndrome (MDS)&#xD;
&#xD;
               -  myelofibrosis&#xD;
&#xD;
          4. Performance Status score of 0 and 1 according to the Eastern Cooperative Oncology&#xD;
             Group (ECOG) scale&#xD;
&#xD;
          5. Able to swallow and retain oral medication.&#xD;
&#xD;
          6. Fasting serum glucose &lt; 126 mg/dL (&lt;7 mmol/L).&#xD;
&#xD;
          7. Male subjects with a female partner of childbearing potential must have had a prior&#xD;
             vasectomy or agree to use adequate contraception from the time of the first dose of&#xD;
             study drug until three months after the last dose of study drug.&#xD;
&#xD;
          8. A female subject is eligible to participate if she is of:&#xD;
&#xD;
               -  Non-childbearing potential&#xD;
&#xD;
               -  Child-bearing potential, has a negative serum pregnancy test during the screening&#xD;
                  period, and agrees to use adequate contraception from screening until four weeks&#xD;
                  after the last dose of study drug.&#xD;
&#xD;
          9. Adequate organ system function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Chemotherapy, radiotherapy, or immunotherapy within 28 days (or 42 days for prior&#xD;
             nitrosoureas or mitomycin C) prior to the first dose of study drug.&#xD;
&#xD;
          2. Use of an investigational anti-cancer drug within 28 days or five half-lives,&#xD;
             whichever is longer, preceding the first dose of study drug.&#xD;
&#xD;
          3. Current use of a prohibited medication or requires any of these medications during&#xD;
             treatment with study drug.&#xD;
&#xD;
          4. Current use of anticoagulants at therapeutic levels within seven days prior to the&#xD;
             first dose of study drug, including warfarin, low molecular weight heparin and direct&#xD;
             thrombin inhibitors. Low dose (prophylactic) anticoagulants are permitted provided&#xD;
             that subject's PT and PTT meet entry criteria.&#xD;
&#xD;
          5. Current use of any anti-platelet agent (e.g. dipyridamole, clopidogrel) other than&#xD;
             aspirin (81 mg daily).&#xD;
&#xD;
          6. Presence of active gastrointestinal disease or other condition that could affect&#xD;
             gastrointestinal absorption (e.g. malabsorption syndrome) or predispose subject to&#xD;
             gastrointestinal ulceration.&#xD;
&#xD;
          7. Any major surgery within the last four weeks.&#xD;
&#xD;
          8. Unresolved toxicity (except alopecia) Grade 2 from previous anti-cancer therapy unless&#xD;
             agreed to by a Medical Monitor and the Investigator&#xD;
&#xD;
          9. Previously diagnosed diabetes mellitus (Type 1 or 2).&#xD;
&#xD;
         10. Current use of oral corticosteroids, with the exception of inhaled or topical&#xD;
             corticosteroids.&#xD;
&#xD;
         11. Any serious or unstable pre-existing medical, psychiatric, or other condition&#xD;
             (including lab abnormalities) that could interfere with subject safety or with&#xD;
             obtaining informed consent.&#xD;
&#xD;
         12. Symptomatic or untreated central nervous system (CNS) involvement by the hematologic&#xD;
             malignancy (including primary CNS lymphoma).&#xD;
&#xD;
         13. Evidence of severe or uncontrolled systemic diseases&#xD;
&#xD;
         14. Known infection with HIV, HBV or HCV.&#xD;
&#xD;
         15. QTc interval â‰¥ 470 msecs.&#xD;
&#xD;
         16. Other clinically significant ECG abnormalities including 2nd degree (Type II) or 3rd&#xD;
             degree atrioventricular (AV) block.&#xD;
&#xD;
         17. History of myocardial infarction, acute coronary syndromes (including unstable&#xD;
             angina), coronary angioplasty, or stenting or bypass grafting within the past six&#xD;
             months.&#xD;
&#xD;
         18. Class III or IV heart failure as defined by the New York Heart Association (NYHA)&#xD;
             functional classification system.&#xD;
&#xD;
         19. Pregnant or lactating female.&#xD;
&#xD;
         20. Active drug or alcohol abuse.&#xD;
&#xD;
         21. History of sensitivity to heparin or heparin-induced thrombocytopenia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S. Jamie Freedman, MD, PhD</last_name>
    <role>Study Director</role>
  </overall_official>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>March 20, 2009</study_first_submitted>
  <study_first_submitted_qc>April 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2009</study_first_posted>
  <last_update_submitted>April 3, 2012</last_update_submitted>
  <last_update_submitted_qc>April 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic lymphocytic leukemia</keyword>
  <keyword>aggressive lymphoma</keyword>
  <keyword>non-Hodgkin's lymphoma</keyword>
  <keyword>Hodgkin's lymphoma</keyword>
  <keyword>chronic myelogenous leukemia</keyword>
  <keyword>multiple myeloma</keyword>
  <keyword>acute lymphoblastic leukemia</keyword>
  <keyword>acute myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

